Search results
Results from the WOW.Com Content Network
May 2018: Results of Phase 2b trial posted; October 2019: Results of Phase 3 trial presented [21] June 2020: Results of second Phase 3 trial published [22] The US Food and Drug Administration (FDA) approved abrocitinib based on evidence from three controlled clinical trials enrolling a total of 1615 participants supporting efficacy and safety. [11]
Necrobiosis lipoidica is a rare, chronic skin condition predominantly associated with diabetes mellitus (known as necrobiosis lipoidica diabeticorum or NLD). [1] It can also occur in individuals with rheumatoid arthritis or without any underlying conditions ( idiopathic ). [ 2 ]
Sunnybrook Research Institute (SRI) is the research component of Sunnybrook Health Sciences Centre in Toronto, Ontario. It is one of the largest research centres in Canada and is fully affiliated with the University of Toronto. The institute employs over 300 scientists and clinician-scientists and has a total of over 1300 research staff. [1]
The DRKS is an open access, free of charge online register for clinical trials and is available both in English and German. DRKS is part of the WHO's ICTRP. The DRKS works with two partner registries in Germany, DeReG (German Registry for Somatic Gene-Transfer Trials) and Clinical Trial Registry of the University Medical Center Freiburg. [4]
The centre also has a focus on cancer prevention, [25] detection and patient education. [26] Various clinical trials are also run out of the centre. [27] Research is conducted through the Odette Cancer Centre research program through Sunnybrook Research Institute. [28] Research spans from the topics of basic genetics, biochemistry and biology ...
Its related research arm, the Ontario Cancer Institute (OCI), works in conjunction with the hospital in a mutually beneficial relationship. Many researchers at the OCI hold appointments at the University of Toronto, often within the Department of Medical Biophysics. The Princess Margaret's research program ranked fourth in terms of the ...
The Lunenfeld-Tanenbaum Research Institute is a medical research institute in Toronto, Ontario and part of the Sinai Health System. It was originally established in 1985 as the Samuel Lunenfeld Research Institute, the research arm of Mount Sinai Hospital, by an endowment from the Lunenfeld and Kunin families. It was renamed to the current name ...
The Institute employs more than 300 people at its research hub at the MaRS Centre in downtown Toronto and funds more than 1,900 scientific staff at hospital-based research institutes and universities around the province. In 2018 it was the highest funder of cancer research in Canada. [3]